Navigation Links
Kendle Appoints Industry Veteran to Lead Asia/Pacific Expansion
Date:1/16/2008

Dr. Ross J. Horsburgh Brings 20 Years of Pharmaceutical and CRO Experience

in Asia/Pacific Region to Key Leadership Role

CINCINNATI, Jan. 16 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced Dr. Ross J. Horsburgh has joined the company as Vice President, Global Clinical Development - Asia/Pacific. In this role, he will lead the company's overall expansion in Asia/Pacific and will provide strategic oversight for its Phase II-III operations in the region, including Melbourne and Sydney, Australia; New Delhi, India; and Beijing, China. In all, Dr. Horsburgh brings 20 years of CRO and pharmaceutical industry experience to Kendle.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

"With a population base of nearly 4.0 billion and R&D spending expected to reach $20 billion by 2013, Asia/Pacific is recognized by our customers as one of the more dynamic regions in which to conduct clinical trials," said Dr. Kendle. "Dr. Horsburgh's extensive clinical development experience and familiarity with the Asia/Pacific region will benefit both our customers and Kendle as we execute on our growth strategy for this pivotal market."

Prior to joining Kendle, Dr. Horsburgh was Regional Medical Director, Asia Pacific for AstraZeneca. In this role, he assembled and led a team of 200 individuals across 13 markets. He also served as head of AstraZeneca's internal clinical research organization, responsible for quality assurance, drug safety, talent management and development, input of the Asian view into global product design, and ultimately, submissions to the U.S. Food and Drug Administration and the European Medicines Agency. Prior to AstraZeneca, Dr. Horsburgh held positions with Ciba and the Auckland Hospital Board. He earned his medical degree from the University of Auckland and his master's and bachelor's degrees from the University of Canterbury.

Dr. Horsburgh will report directly to Dr. Kendle for Asia/Pacific expansion and to Martha Feller, PhD, Senior Vice President, Global Clinical Development for Phase II-III operations. He will be based in Singapore.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions - from first-in-human studies through market launch and surveillance - to help the world's biopharmaceutical companies maximize product life cycles and grow market share.

Our global clinical development business is focused on five regions - North America, Europe, Asia/Pacific, Latin America and Africa - to meet customer needs. We have conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites. Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.

Forward-Looking Statements

This release contains information about management's view of Kendle's future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, those set forth in the "Risk Factors" section of the company's latest Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company's views as of the date of this press release and these views could change. However, while the company may elect to update these forward-looking statements at some point, the company specifically disclaims any obligation to do so other than as required by federal securities laws. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date of this press release.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Kendle Executive Dennis Hurley, DrSc to Present Keynote Address at DIA Latin American Congress 2007
2. Kendle Appoints Ken Hintze, PhD, Vice President, Global Clinical Safety & Pharmacovigilance
3. Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007
4. WorldHeart Appoints David Pellone Chief Financial Officer
5. Novo Nordisk Appoints New Leader of North American Business
6. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
7. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
8. Resonant Medical Appoints New Vice President of Global Sales
9. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
10. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
11. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , ... April 28, 2016 , ... Head Over Heels ... 9 Western Championships. The competition will be held at the University of Montana on ... gymnasts west of the Mississippi River. , In order to qualify, Varize needed to ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... open availability of a new CDISC standard, Clinical Trial Registry (CTR) XML. ... This innovative standard will make it possible to build applications that generate ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cosmetic Town, an online ... cosmetictown.com . The forum section was recently revamped and upgraded to allow even more ... in use across the country. , According to the senior editor of Cosmetic Town, ...
(Date:4/28/2016)... ... 2016 , ... Greener Hydroponics is now offering a large selection of Smart ... organic farmers and nurseries according to Sales Manager Joe Steele who says, “Now is ... is to offer wholesale level pricing and ultra-fast shipping for growers of any size.” ...
(Date:4/28/2016)... ... April 28, 2016 , ... In 2011, TIME magazine ... the emerging field of biomechatronics, technology that marries human physiology with electromechanics. He continues ... He is also the Founder of BionX , a leader in the field ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 ... in Zürich gab Strekin AG den Start ... zur Erhaltung des Resthörvermögens von Patienten, denen ... die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan ... wird während der Operation direkt ins Mittelohr ...
(Date:4/27/2016)... PARIS , April 27, 2016 ... Year-Over-Year Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... today announced its sales for the first quarter ended ... business and the execution of its commercial strategy. ...
(Date:4/27/2016)... 2016 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends, and ... global skincare devices market was valued at US$ 7,255.8 ... a CAGR of 10.1% from 2015 to 2023 to ... the full Skincare Devices Market (Treatment Device - LED Therapy ...
Breaking Medicine Technology: